Bio-Synthesis Inc.

Announces Exclusive Collaboration in the Area of Immune Agonists and

Antagonists

Bio-Synthesis Inc., a closely held biotechnology company, is pleased to announce an exclusive scientific
collaboration with Dr. Dante Marciani, a world renowned expert in immune agonists. Over the last 20
years, Dr. Marciani has pioneered work with proprietary immune stimulatory saponins and their semi-
synthetic analogs that have immune enhancing activities. These small molecule constructs have the
potential to stimulate Th1 immunity thus become an important element in preventive vaccines as well as
active immunotherapy.

These plant-derived glycosides and their analogs have the unique ability to stimulate antigen-specific
CTL production that will seek and destroy cells carrying abnormal markers, such as viral, intracellular
parasites or tumor markers.

Previous work by Dr. Marciani has been effective in stimulating a protective preventive immune
response in commercial products, against various pathogens, such as retroviruses. These molecules have
the capacity to stimulate both humoral and cell-mediated immunity; its inclusion in vaccines may result
in a safe and protective immune response against infection.

The collaboration between Dr. Marciani and BioSynthesis is focused on proprietary novel glycosides
that stimulate innate immunity while taking advantage of the synergistic effects between innate and
adaptive immunity. In addition, the collaboration extends to proprietary compounds that down regulate
Th1 immunity, an area of significance in the treatment of chronic inflammatory conditions.

About Bio-Synthesis

Bio-Synthesis Inc, headquartered in Lewisville, is a closely held company that is a leader in

providing integrated custom synthesis solutions for life science research worldwide. With a vision for
innovation, Bio-Synthesis offers expertise in technologies from oligo synthesis such as DNA, RNA, LNA,
PNA to peptides, antibody, organic synthesis and molecular reagents. BioSynthesis carries a broad line
of chemical modifications, labelings, special synthesis, conjugations, arrays services and reagents for
basic research, high-throughput screening and drug discovery. BSI’s staff of highly experienced and
qualified chemists, biologists and immunologists has reliably and consistently provided products and
services to large pharmaceuticals and universities across the country that meet the most demanding
requirements for quality, turnaround and expert technical support.

For more information, please call Dr. Miguel Castro, BioSynthesis’ President and CEO, 1-800-227-
0627 or visit www.biosyn.com.